Charges for hospital administered drugs.
The impact of HB1328 on state laws will be significant as it introduces a standardized approach to how hospital charges for administered drugs are calculated and billed. By tying the maximum charge to established Medicare rates, the bill aims to enhance transparency in healthcare billing and could lead to reduced out-of-pocket costs for patients. Furthermore, the requirement for hospitals to update their billing amounts biannually based on Medicare rates is expected to ensure ongoing alignment with national reimbursement standards.
House Bill 1328 addresses the issue of hospital charges for administered drugs by setting strict limitations on the billing amounts that hospitals can charge for these drugs. This bill aims to establish a more predictable and fair billing system for patients and insurers alike. Specifically, it prohibits hospitals from billing for an administered drug an amount greater than 120% of the Medicare reimbursement rate or the amount charged for that drug on June 30, 2026, whichever is lower. This measure is set to take effect on July 1, 2026, allowing hospitals to adjust to these new provisions.
While the intention behind HB1328 is to create a fairer billing system, there are potential points of contention. Some healthcare facilities may argue that the bill imposes undue restrictions by limiting their ability to recover costs associated with the use of expensive drugs and treatments. Additionally, concerns may arise regarding the impact of these limitations on hospitals, especially smaller or rural facilities that may already be struggling financially. Stakeholders will likely engage in discussions regarding the balance between cost control and the financial health of hospitals.